North America Hormone Replacement Therapy Market Forecast 2021-2028

Inkwood Research
160 Pages - INKWOOD10103
$1,250.00

KEY FINDINGS
The North America hormone replacement therapy market growth is predicted to progress at a CAGR of 7.47% during the forecast period, 2021-2028. The key market growth drivers are innovations for human growth hormone therapy and testosterone therapy and new drug developments.
MARKET INSIGHTS
Canada and the United States are assessed for the North America hormone replacement therapy market growth analysis. In Canada, Health Canada has approved HRT products for use to treat menopausal symptoms like night sweats, hot flashes, vaginal dryness, and prevent osteoporosis. According to an article, several women were prescribed estrogen with or without progestin HRT to treat menopause symptoms. The two main types of HRT are estrogen without progestin and combined estrogen and progestin.
Progestin is added for uterine cancer prevention in women who never had a hysterectomy. Also, the availability of HRT and the increasing elderly population are boosting the market growth. For instance, by the age of 80, 1 in 10 will be living in a nursing home. Furthermore, the growing R&D activities for hormone replacement products are improving their efficiency and quality. The rising consumer awareness and technological innovations like new gel-based formulations are further contributing to market growth.
COMPETITIVE INSIGHTS
Some of the prominent market players are Pfizer Inc, Viatris Inc (Mylan NV), Amgen, Novo Nordisk A/S, Abbott Laboratories, etc.
Our report offerings include:
• Explore key findings of the overall market
• Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
• Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
• Market Segmentation cater to a thorough assessment of key segments with their market estimations
• Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
• Key analytics: Porter’s Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
• Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
• Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments

'

TABLE OF CONTENTS
1. RESEARCH SCOPE & METHODOLOGY
1.1. STUDY OBJECTIVES
1.2. SCOPE OF STUDY
1.3. METHODOLOGY
1.4. ASSUMPTIONS & LIMITATIONS
2. EXECUTIVE SUMMARY
2.1. MARKET SIZE & ESTIMATES
2.2. MARKET OVERVIEW
3. MARKET DYNAMICS
3.1. KEY DRIVERS
3.1.1. PREVAILING AWARENESS ABOUT POST-MENOPAUSAL ISSUES AMONG WOMEN
3.1.2. INCIDENCE OF HORMONAL DISORDERS
3.1.3. PRODUCT LAUNCHES BY MAJOR PLAYERS
3.2. KEY RESTRAINTS
3.2.1. ADVERSE REACTIONS ASSOCIATED WITH HORMONE REPLACEMENT THERAPY
3.2.2. HIGH COST OF TREATMENT
4. KEY ANALYTICS
4.1. IMPACT OF COVID-19 ON HORMONE REPLACEMENT THERAPY MARKET
4.2. KEY MARKET TRENDS
4.3. PORTER’S FIVE FORCES ANALYSIS
4.3.1. BUYERS POWER
4.3.2. SUPPLIERS POWER
4.3.3. SUBSTITUTION
4.3.4. NEW ENTRY
4.3.5. INDUSTRY RIVALRY
4.4. OPPORTUNITY MATRIX
4.5. VENDOR LANDSCAPE
5. MARKET BY THERAPY TYPE
5.1. ESTROGEN HORMONE REPLACEMENT THERAPY
5.2. THYROID HORMONE REPLACEMENT THERAPY
5.3. TESTOSTERONE HORMONE REPLACEMENT THERAPY
5.4. HUMAN GROWTH HORMONE REPLACEMENT THERAPY
5.5. PROGESTOGEN HORMONE REPLACEMENT THERAPY
6. MARKET BY INDICATION
6.1. MENOPAUSE
6.2. MALE HYPOGONADISM
6.3. GROWTH HORMONE DEFICIENCY
6.4. HYPOTHYROIDISM
6.5. OTHER INDICATIONS
7. MARKET BY ROUTE OF ADMINISTRATION
7.1. ORAL
7.2. PARENTERAL
7.3. TRANSDERMAL
7.4. OTHER ROUTE OF ADMINISTRATIONS
8. GEOGRAPHICAL ANALYSIS
8.1. NORTH AMERICA
8.1.1. MARKET SIZE & ESTIMATES
8.1.2. KEY GROWTH ENABLERS
8.1.3. KEY CHALLENGES
8.1.4. KEY PLAYERS
8.1.5. COUNTRY ANALYSIS
8.1.5.1. UNITED STATES
8.1.5.2. CANADA
9. COMPETITIVE LANDSCAPE
9.1. KEY STRATEGIC DEVELOPMENTS
9.1.1. MERGERS & ACQUISITIONS
9.1.2. PRODUCT LAUNCHES & DEVELOPMENTS
9.1.3. PARTNERSHIPS & AGREEMENTS
9.1.4. BUSINESS EXPANSIONS, ANNOUNCEMENTS & DIVESTITURES
9.2. COMPANY PROFILES
9.2.1. ABBOTT LABORATORIES
9.2.2. AMGEN
9.2.3. ANI PHARMACEUTICALS
9.2.4. BAYER AG
9.2.5. ELI LILLY & COMPANY
9.2.6. GENENTECH INC
9.2.7. IPSEN
9.2.8. MERCK KGAA
9.2.9. NOVARTIS AG
9.2.10. NOVEN PHARMACEUTICALS INC
9.2.11. NOVO NORDISK A/S
9.2.12. PFIZER INC
9.2.13. VIATRIS INC (MYLAN NV)

1. ABBOTT LABORATORIES
2. AMGEN
3. ANI PHARMACEUTICALS
4. BAYER AG
5. ELI LILLY & COMPANY
6. GENENTECH INC
7. IPSEN
8. MERCK KGAA
9. NOVARTIS AG
10. NOVEN PHARMACEUTICALS INC
11. NOVO NORDISK A/S
12. PFIZER INC
13. VIATRIS INC (MYLAN NV)

$1,250.00

Research Assistance

We can help you find
data and analyses
relevant to your needs,
or prepare a custom report.

Please contact us at [email protected]
or +1 212 564 2838

 

Custom Research

Contact us to speak
with your industry analyst.

[email protected] 
+1 212 564 2838

 



Discount Codes

Request Discount Codes
for reports of interest to you.

[email protected]
+1 212 564 2838